First successful case of platinum-based chemotherapy for neuroendocrine prostate cancer with BRCA2 and PTEN alterations

4Citations
Citations of this article
10Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Introduction: Deoxyribonucleic acid repair gene mutations are now being studied in a variety of solid tumors, with the hope of predicting prognosis, pathogenesis, and treatment outcomes. Case presentation: We report the case of a Japanese patient with advanced castration-resistant prostate cancer who exhibited a prominent response to platinum therapy and had coexisting BRCA2 and PTEN mutations according to retrospective multigene panel analysis. Conclusion: Through a review of clinical outcomes and genetic/pathologic profiling, the presented case provides insights into future management strategies based on the tumor genetic status.

References Powered by Scopus

Integrative clinical genomics of advanced prostate cancer

2588Citations
N/AReaders
Get full text

The Molecular Taxonomy of Primary Prostate Cancer

2345Citations
N/AReaders
Get full text

DNA-repair defects and olaparib in metastatic prostate cancer

1824Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Addressing the need for more therapeutic options in neuroendocrine prostate cancer

3Citations
N/AReaders
Get full text

An Overview of Altered Pathways Associated with Sensitivity to Platinum-Based Chemotherapy in Neuroendocrine Tumors: Strengths and Prospects

2Citations
N/AReaders
Get full text

Brain metastasis in a patient with BRCA2-mutated treatment-related neuroendocrine prostate carcinoma and long-Term response to radiotherapy and Olaparib: A case report and literature review

0Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Omura, M., Kosaka, T., Aimono, E., Nakamura, K., Hongo, H., Mikami, S., … Oya, M. (2022). First successful case of platinum-based chemotherapy for neuroendocrine prostate cancer with BRCA2 and PTEN alterations. IJU Case Reports, 5(1), 41–44. https://doi.org/10.1002/iju5.12383

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 1

50%

Researcher 1

50%

Readers' Discipline

Tooltip

Biochemistry, Genetics and Molecular Bi... 3

60%

Medicine and Dentistry 1

20%

Pharmacology, Toxicology and Pharmaceut... 1

20%

Save time finding and organizing research with Mendeley

Sign up for free